Skip to content
Combination Therapy Shows Promise Against Osteosarcoma

Combination Therapy Shows Promise Against Osteosarcoma

First seen 20 Oct 2026, 15:52 UTC • •
API

Article Content

Browse articles
ThreatCluster AI
ThreatCluster •October 20, 2026 at 22:21 UTC
  • •Combination therapy targets EP300 and AKT pathways in osteosarcoma.
  • •Research shows significant tumor growth reduction in preclinical models.
  • •Potential biomarkers identified for treatment sensitivity in specific tumor mutations.

Researchers at St. Jude Children's Research Hospital have identified a potential therapeutic vulnerability in osteosarcoma, a challenging pediatric bone cancer. Their study, published in the Journal of Experimental Medicine, reveals that a combination therapy targeting the EP300 protein and inhibiting the AKT pathway significantly slowed tumor growth and increased survival in preclinical models. This approach is particularly relevant for patients with metastatic disease, who typically have poor outcomes. The findings suggest that specific genetic mutations in tumors may serve as biomarkers for treatment sensitivity. As no new treatments for osteosarcoma have been approved in the last 40 years, this research offers a new avenue for therapeutic exploration.

Start a free Starter trial for enhanced analysis

Ask AI about this cluster

Updated just now How this analysis works

Timeline

2026-10-20
Study published in Journal of Experimental Medicine
St. Jude researchers published findings on a combination therapy for osteosarcoma, showing promising results in preclinical models.
Newswise

More articles in this cluster (2)

Extracted Entities

1 / 2

Common questions

What is the significance of targeting EP300 and AKT?
Targeting these proteins may provide a new therapeutic strategy for treating osteosarcoma, especially in cases resistant to current therapies.
What are the implications for patients with metastatic osteosarcoma?
This research offers hope for improved treatment options for patients with metastatic disease, who currently have limited effective therapies.
How can genetic mutations serve as biomarkers?
The study suggests that certain mutations may indicate which tumors are more likely to respond to the combination therapy, guiding treatment decisions.